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Engrafted human cells generate adaptive
immune responses to Mycobacterium bovis BCG
infection in humanized mice
Jinhee Lee1*, Michael A Brehm2, Dale Greiner2, Leonard D Shultz3 and Hardy Kornfeld1
Abstract
Background: Currently used mouse models fail to fully reflect human immunity to tuberculosis (TB), which hampers
progress in research and vaccine development. Bone marrow-liver-thymus (BLT) mice, generated by engrafting human
fetal liver, thymus, and hematopoietic stem cells in severely immunodeficient NOD/SCID/IL-2Rγ−/− (NSG) mice, have
shown potential to model human immunity to infection. We engrafted HLA-A2-positive fetal tissues into NSG mice
transgenically expressing human leukocyte antigen (HLA)-A2.1 (NSG-A2) to generate NSG-A2-BLT mice and characterized
their human immune response to Mycobacterium bovis bacillus Calmette-Guerin (BCG) infection to assess the utility of
this model for investigating human TB.
Results: NSG-A2-BLT mice were infected intravenously with BCG and the immune response of engrafted human
immune cells was characterized. After ex vivo antigenic stimulation of splenocytes, interferon (IFN)-γ-producing cells
were detected by ELISPOT from infected, but not uninfected NSG-A2-BLT mice. However, the levels of secreted IFN-γ,
determined by ELISA, were not significantly elevated by antigenic stimulation. NSG-A2-BLT mice were susceptible to BCG
infection as determined by higher lung bacillary load than the non-engrafted control NSG-A2 mice. BCG-infected
NSG-A2-BLT mice developed lung lesions composed mostly of human macrophages and few human CD4+ or CD8+ T
cells. The lesions did not resemble granulomas typical of human TB.
Conclusions: Engrafted human immune cells in NSG-A2-BLT mice showed partial function of innate and adaptive
immune systems culminating in antigen-specific T cell responses to mycobacterial infection. The lack of protection was
associated with low IFN-γ levels and limited numbers of T cells recruited to the lesions. The NSG-A2-BLT mouse is
capable of mounting a human immune response to M. tuberculosis in vivo but a quantitatively and possibly qualitatively
enhanced effector response will be needed to improve the utility of this model for TB research.
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Background
Tuberculosis (TB), caused by Mycobacterium tuberculosis
(Mtb), remains a serious human health threat, killing 1.4
million people annually (Tuberculosis Fact Sheet, 2011,
World Health Organization, Geneva, Switzerland). Despite
numerous TB vaccine candidates being tested, the pros-
pects for their success have dimmed following the failure of
the MV85ATB vaccine in a recent clinical trial [1]. A major
obstacle to TB vaccine development is the incomplete
understanding of the human immune response to TB and
the correlates of protection.
Animal models, including mice, guinea pigs, rabbits
and non-human primates have contributed to our
current knowledge on Mtb-host interactions. The avail-
ability of genetically modified mice enabled researchers
to identify crucial components of protective immunity
including interferon (IFN)-γ, tumor necrosis factor
(TNF)-α, and interleukin (IL)-12 [2]. The roles of these
factors have been verified in humans with mutations in
the IFN-γ or IL-12 receptor genes and in patients treated
with TNF-α blockers [3,4]. Despite the usefulness of trad-
itional animal models, they are criticized for not accurately
reflecting human TB. The most critical difference lies in
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their homogenous susceptibility; 100% of mice, rabbits
and guinea pigs infected with Mtb develop disease and
eventually die with progressive lung pathology, while only
5-10% of Mtb-infected humans develop active TB disease
[5]. Most infected individuals mount an effective immune
response that maintains latency throughout their lifespan
[5]. Latent TB infection is a unique feature of human TB,
for which there is no optimal animal model. Non-human
primates are capable of enforcing latency but nonetheless
have a much higher rate of TB progression than humans,
while rodent models are incapable of enforcing latency [6].
Another characteristic feature of human TB is the for-
mation of organized, caseating granulomas with a ma-
crophage core and a peripheral rim of lymphocytes [7].
Although TB lesions in mice contain macrophages and
lymphocytes, they are poorly organized and generally not
necrotic. Non-human primate (NHP) models mirror
human TB pathology, but the use of NHP is limited by
high cost and the lack of genetic models. These consi-
derations emphasize the need for new and more tractable
animal models that better reflect the unique features of
human immunity to TB.
Recent advances in humanized mice hold promise for
an enhanced model of human immunity. Successful
human cell engraftment requires an immunodeficient
recipient. Advances in humanized mouse models have
followed the generation of mouse strains with increas-
ingly broader deficiency in host innate immunity and
expression of human-specific cytokines and other factors.
Attempts to engraft mice with human hematopoietic cells
began with CB-17-Prkdcscid , severe combined immune
deficiency, (SCID) mice as recipients, but results were
limited by the development of functional mouse lym-
phocytes, moderate NK cell activity, and only limited
engraftment [8]. Subsequently, the scid mutation was
backcrossed onto the NOD strain and combined with the
IL2rgTm1Wjl (IL2rγnull) mutation to create the NOD-SCID-
IL2rγnull strain [9]. The most advanced engraftment iter-
ation of this model employs mice engrafted with human
fetal thymus and liver followed by transplantation of
autologous CD34+ hematopoietic stem cells (HSC), termed
BLT (bone marrow-liver-thymus) mice [10]. NSG-BLT
mice develop a human immune system with a more
complete range of human T cells, B cells, dendritic cells
(DC), monocytes and macrophages as well as improved en-
graftment of secondary lymphoid organs. They are capable
of mounting adaptive immune responses to infection with
Epstein Barr virus (EBV) and human immunodeficiency
virus (HIV) [10,11]. A compelling application has been for
HIV research: humanized mice support HIV replication
after mucosal infection with subsequent CD4+ T cell
depletion [12,13].
In the current study, we explored the feasibility of
using humanized mice for TB research. Toward this
end, we investigated whether engrafting human immune
cells in NSG-BLT mice elicits 1) cellular responses to
Mtb that 2) lead to protection against the pathogen. In
an attempt to maximize human immune responses, we
engrafted NSG mice expressing HLA-A2.1 molecules
(NSG-A2) with HLA-2-positive fetal tissues to enable
engrafted HLA-A2-restricted human T cells to recognize
murine HLA-A2+ phagocytes infected with Mtb. We re-
port here the generation of Mtb-specific human cellular
immune responses in NSG-A2-BLT mice, but these
responses did not translate into the control of BCG
growth or human-like granuloma formation, which might
be due to insufficient recruitment of T cells to the lesion
and low IFN-γ production.
Results
Engrafted human immune cells in NSG-A2-BLT mice
mount an acquired immune response to BCG infection
To evaluate the utility of NSG-A2-BLT mice as an animal
model for TB, we assessed the response of engrafted
human immune cells to infection with BCG. NSG-A2 and
NSG-A2-BLT mice were infected with BCG intravenously
(i.v.) at a dose of 1 × 105 colony-forming units (CFU) and
euthanized four weeks post-infection to measure bacterial
load in the lung, and human adaptive immune responses.
Splenocytes from infected NSG-A2-BLT mice responded
to ex vivo restimulation with mycobacterial antigens by
producing IFN-γ as measured by ELISPOT, while spleno-
cytes from uninfected NSG-A2-BLT mice did not produce
measurable IFN-γ in response to any of these antigens
(Figure 1A). Splenocytes from BCG infected mice had a
stronger response to activation by PMA/ionomycin than
splenocytes from uninfected mice, indicating an expansion
of non-antigen-specific Th1 cells from infected NSG-A2-
BLT mice. Splenocytes from infected NSG-A2-BLT mice
did not produce IFN-γ without antigenic stimulation.
Unlike the ELISPOT result, the levels of IFN-γ secreted
into media in response to ex vivo antigenic stimulation
measured by ELISA were not statistically higher than in
the media control (Figure 1B). Splenocytes stimulated
with PMA/ionomycin produced large amounts of IFN-γ,
indicating the presence of functionally competent T
cells capable of secreting IFN-γ. To determine if NSG-
A2-BLT mice acquired the capacity to restrict BCG
replication, we compared lung bacillary load in NSG-
A2-BLT mice and NSG-A2 mice 4 weeks after BCG
infection. Rather than demonstrating enhanced control
of BCG, the lungs of NSG-A2-BLT mice had higher
CFU counts than the non-engrafted NSG-A2 controls
(Figure 2). This unexpected result implies that the en-
grafted human immune cells are unable to kill intracellular
bacilli, instead providing an environment more conducive
for replication than host murine macrophages.
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BCG-infected NSG-A2-BLT mice develop lesions in the
lungs that are not typical granulomas
Human granulomas are not reproduced in murine models
of TB [5]. We sought to determine whether engrafted hu-
man immune cells develop lesions resembling human
granulomas. Lung tissue sections were prepared for H&E,
Ziehl-Neelsen (“acid-fast”), and immunostaining for hu-
man immune cell markers (Figure 3). H&E staining
revealed inflammatory lesions in the lungs of BCG-
infected NSG-A2-BLT mice (Figure 3A). No lesions were
found in uninfected NSG-A2-BLT mice (data not shown).
Non-engrafted NSG-A2 mice infected with BCG had mye-
loid cell aggregates that were smaller and less frequent
than the lesions in NSG-A2-BLT mice. When compared
with lesions in immunocompetent C57BL/6 mice infected
with BCG in parallel, the lesions of NSG-A2-BLT mice
were less frequent but comparable in size, and appeared to
be more compact (Figure 3A). Ziehl-Neelsen staining in
NSG-A2-BLT mouse lung sections showed that bacilli
were scattered throughout the lung, inside and outside
areas of inflammation, indicating that the lesions did not
prevent spreading of infection. To evaluate human cell re-
cruitment, serial lung sections from NSG-A2-BLT mice
were stained with human-specific antibodies against CD4,
CD8, and CD68 followed by colorimetric (Figure 3B) and
fluorescent detection (Figure 3C). The lesions of NSG-
A2-BLT mice contained abundant CD68+ human macro-
phages, but few to no detectable human CD4+ and CD8+
cells. All three antibodies produced negligible signals in
lung sections from BCG-infected C57BL/6 mice, confirm-
ing their specificity for human antigens (Figure 3C). No
caseous necrosis was observed. Collectively, the lesions
induced by BCG in NSG-A2-BLT mice were less well
developed than human granulomas.
Human macrophages promote BCG growth
We hypothesized that the lack of protection and higher
BCG growth in NSG-A2-BLT mice relative to non-
engrafted NSG-A2 mice was due to residual mouse-origin
macrophages concealing BCG from human adaptive im-
mune responses despite the expression of human HLA-A2
in both strains. To test that hypothesis, we compared the
relative abundance of mouse and human macrophages
in the lungs of NSG-A2-BLT mice. Mouse and human
macrophages were visualized by staining with anti-mouse
F4/80 and anti-human CD68 antibody. Without infection,
the frequencies of mouse and human macrophages in the
lungs were comparable and low (Figure 4A). On the other
hand, human macrophages outnumbered murine macro-
phages in the lesions of BCG-infected mice (Figure 4A).
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Figure 1 NSG-A2-BLT mice mount adaptive immune responses
to BCG infection. NSG-A2-BLT mice were infected i.v. with BCG at a
dose of 1 × 105 CFU per mouse. One month later mice were sacrificed,
and T cell recall response of splenocytes was measured by ELISPOT
(n = 6 for infected NSG-A2-BLT mice and n = 2 for uninfected NSG-A2-
BLT mice) (A) and ELISA (n = 3 for infected NSG-BLT mice) (B). Culture
conditions and antigenic stimulation are described in Methods.
Abbreviations: CFP, Culture filtrate proteins; WC, Heat-killed whole BCG;
PMA, Phorbol 12-myristate 13-acetate; Iono, ionomycin. *p < 0.05.
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Figure 2 NSG-A2-BLT mice had a higher BCG load in the lung
than A2-NSG mice. NSG-A2-BLT and A2-NSG mice were infected as
indicated in Figure 1, and sacrificed to collect lungs to measure the
bacterial load. n = 6 for A2-NSG mice and n = 4 for NSG-A2-BLT mice.
*p < 0.05.
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When lung sections were stained with anti-PPD to
visualize BCG bacilli, a large number of BCG bacilli were
found in the lung lesions (Figure 4B). This observation
suggests that human macrophages recruited to the site of
infection support BCG growth better than murine macro-
phages. In C57BL/6 mice infected with BCG in parallel
with NSG-A2-BLT mice, there were much fewer BCG
bacilli found in the lung lesions due to efficient adaptive
immune responses (Figure 4B). Thus, NSG-A2-BLT mice
likely lack efficient T cell effector function at the site of
infection.
Even though human macrophages were the dominant
macrophage population in lesions, murine macrophages
were still present (Figure 4A). Murine macrophages
could be a major site for BCG replication since they
would be less responsive to the effector functions of
human T cells. To address that possibility, we used NSG
mice transgenically expressing human colony stimulating
factor-1 (CSF-1) to generate NSG-CSF1-BLT mice with
an expanded human macrophage population. NSG-
CSF1-BLT mice had significantly higher levels of human
macrophages both in percentages and numbers in the
spleen at 16 weeks post-implant (Figure 5A-C). How-
ever, BCG load was not reduced in the lungs and spleens
of NSG-CSF1-BLT mice, compared to NSG-CSF1 mice,
and in fact were higher in the spleen of NSG-CSF1-BLT
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Figure 3 NSG-A2-BLT mice develop lung lesions in response to BCG infection. Mice were infected as indicated in Figure 1, and sacrificed
for histopathological examination. Lungs were inflated in 10% formalin, and embedded in paraffin for making thin sections. A. H&E stains on
NSG-A2, NSG-A2-BLT, and C57BL/6 mice (100× and 20×, scale bars = 100 μm and 500 μm, respectively). Blue arrows indicate BCG lesions. B. Serial
lung sections from NSG-A2-BLT mice infected with BCG were stained for H&E, Acid Fast bacilli, and immunohistochemistry for human CD68,
human CD4, and human CD8. Immunostaining was visualized by colorimetric detection. Red arrows indicate BCG bacilli (200×, scale bars = 50 μm).
C. Serial lung sections from NSG-A2-BLT and C57BL/6 mice infected with BCG were stained with human-specific antibodies against CD4, CD8, and CD68
followed by secondary antibody labeled with Alexa 555, and examined by fluorescence microscopy (200×, scale bar = 50 μm). Images are representative
of tissues from four animals.
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mice (Figure 5D and E). This suggests that the residual
murine macrophages had a minimal impact on the pro-
tective immune response mediated by the engrafted
human immune cells.
Discussion
Immunocompetent rodent models fail to accurately
reproduce all of the features of human TB, which pre-
sents a major obstacle to their use in TB research. Hu-
manized small animal models have shown potential to
study functions of human immune cells and tissues in
other infectious diseases [14-16]. Thus, we evaluated the
utility of NSG-A2-BLT mice for TB research. We show
for the first time that a human immune system in mice
can mount an antigen-specific T cell response to myco-
bacterial infection. In addition, human macrophages are
recruited to the site of infection forming a macrophage
mass, an early phase of granuloma formation. These
observations warrant further efforts to refine humanized
murine models to study human immunity to TB.
It is encouraging that NSG-A2-BLT mice mounted an
antigen-specific T cell response to mycobacterial infection.
Previous studies of engrafted human immune cells in mice
infected with mycobacteria reported only non-antigen-
specific polyclonal T cell activation [17,18]. Priming of
antigen-specific T cells requires a multitude of functional-
ities of both antigen-presenting cells and T cells. DCs are
equipped with danger signaling pathways, HLAs and cost-
imulatory molecules, and proinflammatory cytokines that
augment antigen presentation [19,20]. It has been shown
that NSG-BLT mice mount recall responses to viral infec-
tion and immunization with proteins [10,11]. Our report
adds one more infection model where NSG-BLT mice can
develop a human adaptive immune response to the infec-
tious agent. The elicitation of in vitro recall responses to
both secreted Mtb proteins and heat-killed BCG implies
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Figure 4 Human macrophages are the dominant mononuclear cells in the lesions that promote BCG growth. A. Lung sections prepared
from NSG-A2-BLT mice infected with BCG as described in Figure 1 were stained with FITC-labeled anti-human CD68 and FITC-labeled anti-mouse
F4/80 (200×, scale bars = 50 μm) (A). Lung sections were stained with anti-PPD antibody followed by secondary antibody labeled with Alexa 555.
DAPI was used for counter staining (200×, scale bars = 50 μm) (B). Images are representative of tissues from four animals.
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that human DCs are capable of processing multiple anti-
genic forms and presenting Mtb epitopes to naïve human
T cells that are capable of priming.
Despite the presence of antigen-specific IFN-γ produc-
tion by human T cells, NSG-A2-BLT mice were no more
capable of restricting BCG replication than non-engrafted
NSG-A2 controls. Healthy people and immunocompetent
mouse strains are capable of controlling BCG infection,
while immunocompromised mice, such as SCID mice, are
susceptible to BCG, succumbing to infection around
70 days post-infection [21]. Protective immunity to BCG
represents a minimum level of protective immunity
against mycobacterial infection, which NSG-A2-BLT mice
cannot achieve. Killing of intracellular Mtb requires both
innate and adaptive immune components. Human macro-
phages utilize the vitamin D pathway and autophagy,
which are induced after TLR and IFN-γ stimulation
[22-24]. While NSG-A2-BLT mice used in this study were
fed chow containing vitamin D, the potential for further
supplementation to enhance immunity remains to be
tested. Regarding adaptive immunity, TB defense depends
on the magnitude and quality of the T cell response [25].
Using knockout mice, it has been established that CD4+
and CD8+ T cells are critical components of anti-
mycobacterial immunity with CD4+ T cells being more
critical than CD8+ T cells [26] and mice lacking Th1
cytokines (e.g., IFN-γ, TNF-α) rapidly succumb to Mtb
infection [27,28]. These findings are consistent with
Mendelian susceptibility to mycobacterial infection in
humans [3]. We showed by ELISA that levels of IFN-γ
were not significantly induced in response to antigenic
stimulation. The observation that PMA/ionomycin
stimulated T cells to secrete a large amount of IFN-γ
suggests that suboptimal T cell priming and/or expansion
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Figure 5 Transgenic expression of CSF-1 does not improve the protection against BCG in NSG-BLT mice. NSG-BLT and NSG-CSF1-BLT
mice were generated as described in the Methods section. At 16 weeks spleens from NSG-CSF1-BLT mice were recovered and tested for human
cell engraftment (A) and human macrophage development (B and C). Human macrophage were defined as CD14+/CD33+ and the (B) percentage
and (C) number of positive cells are shown. NSG-CSF1 and NSG-CSF1-BLT mice were infected with BCG and bacterial loads in the lung (D) and spleen
(E) were measured by CFU assay (D). N = 4 for NSG-CSF1 and NSG-CSF1-BLT mice. *p < 0.05.
Lee et al. BMC Immunology 2013, 14:53 Page 6 of 11
http://www.biomedcentral.com/1471-2172/14/53
of antigen-specific T cells may be responsible for the de-
creased IFN-γ production capacity of T cells. Since DCs
play a critical role in T cell priming [20], more in-depth
evaluation of DC functions in NSG-A2-BLT mice may
shed light on the lack of protective immunity to infection.
Our data suggest that human macrophages in NSG-
A2-BLT mice promoted BCG growth. Heuts et al. [18]
similarly reported that lung BCG loads were higher in
NSG mice engrafted with human CD34+ HSCs than in
non-engrafted NSG controls, which they attributed to
dysfunctional CD4+ T cells. In addition to the potential
role of dysfunctional CD4+ T cells resulting in an in-
creased bacterial load, we propose that the higher BCG
growth in the humanized mice may also lie in the pres-
ence of human macrophages. We previously showed that
resident alveolar macrophages are the initial target cells
for Mtb infection and growth, but are quickly replaced
as major Mtb infected cells by macrophages and DCs
newly recruited to the lung [29]. In the current study, we
show that the lesions were mostly composed of newly
recruited human macrophages with few to no mouse mac-
rophages. This homing capability of human macrophages
provides niche for BCG growth, as the dominant growth
of BCG bacilli took place in the lesions. On the other
hand, less developed lung lesions seen in NSG-A2 mice
reflect compromised macrophage homing, resulting in
limited BCG growth. The lesions of C57BL/6 mice con-
tained few bacteria, indicative of protective acquired mur-
ine immune responses. Based on poor T cell recruitment
in the lesions and low IFN-γ production, NSG-A2-BLT
mice appear to lack optimal functional adaptive immune
responses, allowing rapid BCG growth. The higher bacter-
ial load in NSG-A2-BLT mice shown in this study para-
doxically demonstrates the functionality of certain aspects
of human immune responses including tissue homing and
phagocytosis of bacteria. In this regard, NSG-A2-BLT
mice may serve as a system to study early events in human
Mtb infection prior to the induction of adaptive immunity
that is protective. This condition cannot be directly stud-
ied in the human host.
Granulomas, a hallmark of immunity to TB, are cellu-
lar structures that limit Mtb dissemination and growth
[2,30]. In humans, granulomas start as an accumulation
of macrophages recruited to the site of infected alveolar
macrophages, which are subsequently surrounded by
antigen-specific and non-specific T cells [2,30,31]. Ana-
lysis of lung tissue sections from NSG-A2-BLT mice
revealed that human macrophages were preferentially re-
cruited relative to CD4+ and CD8+ T cells. The scarcity
of human T cells observed at the sites of infection sug-
gests defects in T cell chemotaxis, perhaps due to sub-
optimal expression of chemokines and/or chemokine
receptors. In human granulomas, bacilli are confined in
the core of the macrophage mass, and caseous necrosis
is often observed. In our study, BCG bacilli were seen in
the outer rim of lesions and no caseous necrosis was ob-
served in NSG-A2-BLT mice. In its present iteration, the
NSG-A2-BLT model does not recapitulate the gra-
nuloma formation that typifies human TB pathology.
Recently, two independent studies reported granuloma
formation in mice engrafted with human immune cells.
Heuts et al. infected NSG mice engrafted with human
cord blood as a source of HSC either with 1 × 106 BCG
i.v. or with a low dose of Mtb by aerosol. Calderon et al.
infected NSG-BLT mice intranasally with 1 × 106 Mtb
H37Rv expressing tdTomato [17]. Although the two
studies shows certain aspects of human granulomas in
the liver, including cellular cuffing, central necrosis, and
giant cell formation, neither study provided images of
lung lesions that mirror human granulomas. It appears
that tissue necrosis is limited to Mtb infection. Like
Heuts et al., we did not observe tissue necrosis when
BCG was used, whereas Heuts et al. and Calderon et al.
observed necrosis with Mtb infection. This is in agree-
ment with our previous report that Mtb more strongly
induces macrophage necrosis than BCG [32]. Relatively
low frequencies of T cells in our study could be due to
the low BCG dose (1 × 105 bacilli) we used. As antigen-
specific CD4 T cells are critical to human granuloma
formation [33], it would be of value to investigate if
enhanced priming of CD4 T cells would enhance T cell
migration into inflammatory sites leading to formation
of more rigorous, structured lesions.
Humanized mouse models are rapidly evolving but
still have significant limitations for TB research [16].
Potential reasons for the failure to express protective
immunity include the lack of human hematopoietic
growth factors and tissue specific chemokines, and poor
lymph node development. A role for relative CSF defi-
ciency in the susceptibility of NSG-A2-BLT mice is in-
triguing since CSF-1, granulocyte CSF (G-CSF), and
granulocyte macrophage CSF (GM-CSF) are all primar-
ily produced by non-hematopoietic cells [34,35]. CSF-1
is the primary regulator of mononuclear phagocyte
production and its function has been elucidated with
CSF1-deficient op/op mice and CSF-1 knockout mice
[34,36]. The op/op mice display unstressed osteopetro-
tic, hematopoietic, tissue macrophages, and abnormal
reproductive phenotypes. CSF-1 regulates the morph-
ology and functions of mononuclear phagocytes and is
necessary for immunity against intracellular fungal, bac-
terial, and viral infections in mice reviewed in ([37,38]).
Episomal expression of CSF-1 enhances cytotoxicity,
superoxide production, phagocytosis, chemotaxis and
cytokine production in monocytes and macrophages
[39,40]. We show that NSG-CSF1-BLT mice had en-
hanced relative frequencies of human macrophages.
Notwithstanding, NSG-CSF1-BLT mice still could not
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reduce the bacterial load compared to non-engrafted
NSG-CSF1 mice. This excludes the possibility that hu-
man CSF-1 deficiency underlies the lack of protective
immunity and granuloma formation in infected NSG-
A2-BLT mice. Human GM-CSF and G-CSF are deficient
in NSG-A2-BLT mice as evidenced by only low levels of
circulating human neutrophils [41]. Although the ab-
sence of GM-CSF does not affect normal hematopoiesis,
GM-CSF−/− mice have numerous defects including a
defect in alveolar macrophage maturation, impaired
proliferative responses of CD4+ T cells to specific anti-
gens after immunization [42,43], and more importantly,
increased susceptibility to Mtb infection [44]. There-
fore, transgenic expression of human GM-CSF might
improve the expression of human immunity to myco-
bacterial infection in NSG-A2-BLT mice, a hypothesis
we are currently testing.
Conclusions
This study provides supporting data on the potential of
humanized mice as an animal model for TB. NSG-A2-
BLT mice developed an adaptive immune response to
BCG infection. However, this response did not provide
protection against infection. Future studies are being
directed toward identifying essential immune compo-
nents in NSG-A2-BLT mice required for more robust
human immunity.
Methods
Animals and human fetal tissues
Immunodeficient NOD.Cg-PrkdcscidIl2rgtm1Wjl/Sz (NSG)
mice and NSG mice transgenically expressing HLA-A2.1
(NSG-A2) or human CSF-1 transgenic (NOD.Cg-Prkdcscid
Il2rgtm1Wjl Tg(CSF1)/Sz , abbreviated as NSG-CSF1, mice
were obtained from colonies developed and maintained
by Dr. Leonard Shultz at The Jackson Laboratory (Bar
Harbor, ME). All animals were housed in a specific
pathogen free facility in microisolator cages, and given
autoclaved food and maintained on acidified autoclaved
water and sulfamethoxazole-trimethoprim medicated
water (Goldline Laboratories, Ft. Lauderdale, FL) pro-
vided on alternate weeks. All animal use was in accord-
ance with the guidelines of the Animal Care and Use
Committee of the University of Massachusetts Medical
School and The Jackson Laboratory and conformed to
the recommendations in the Guide for the Care and Use
of Laboratory Animals (Institute of Laboratory Animal
Resources, National Research Council, National Academy
of Sciences, 1996). Human fetal thymus and liver tissues
were obtained from Advanced Bioscience Resources
(Alameda, CA) or StemExpress, Placerville, CA. Proto-
cols involving the use of human tissues were approved
by the University of Massachusetts Medical School
Institutional Review Board.
Generation of NSG-BLT mice
NSG-A2 and NSG-CSF-1 transgenic mice at 6–8 weeks
of age were irradiated (200 cGy) and surgically im-
planted under the kidney capsule with 1-mm3 fragments
of human fetal thymus and liver on the same day as the
tissues were received. On the same day as the tissue
transplant, CD3-depleted hematopoietic cells derived
from autologous fetal liver were injected i.v. into the
mice to achieve 1 to 5 × 105 CD34+ cells, (we do not
positively select) as a source of hematopoietic stem cells
(HSC). Human cells were allowed to engraft and to gen-
erate an immune system in recipient mice for at least
12 weeks, at which time human hematolymphoid en-
graftment was validated by flow cytometry on peripheral
blood as described previously [45]. The thymic implants
in the NSG-BLT mice grew substantially from the initial
size of 1 mm3 to over 5 mm3, and histological analysis
revealed that the human thymic tissue was heavily popu-
lated with human CD45+ lymphocytes. Spleens of NSG-
BLT mice contained human B cells and T cells (both CD4+
and CD8+ single-positive), macrophages (CD14+/CD33+)
and both conventional (CD11c+) as well as plasmacytoid
(CD123+ ) DC. Successfully engrafted mice based on a
minimum of 20% human CD45+ cells in peripheral blood
were then distributed into various groups based on engraft-
ment levels.
BCG infection
M. bovis BCG Pasteur was grown in Middlebrook 7H9
basal medium (DIFCO; Beckton Dickinson, Sparks, MD)
supplemented with OADC (oleic acid, albumin, dex-
trose, and catalase). BCG bacilli were washed with PBS
containing 0.05%. Tween 80 (PBS-T80), aliquoted in
freezing vials and stored at −70°C until use. For deter-
mination of bacterial concentration in the stock, one vial
was thawed after 24 hours and the concentration of
bacilli was determined by serial dilution followed by
plating on 7H11 agar supplemented with OADC. For in-
fection, aliquots of frozen BCG stock in PBS-T80 were
thawed and sonicated for 1 min in a cup-horn sonifier
(Branson Ultrasonics Corporation, Danbury, CT) to re-
move clumps. Mice were infected i.v. with BCG at 1 × 105
CFU per mouse.
ELISPOT/ELISA assay
IFN-γ-secreting cells were quantified using an IFN-γ
Ab ELISPOT pair (Mabtech, Nacka Strand, Sweden),
MultiScreen-IP ELISPOT plates (Millipore, Billerica,
MA), streptavidin-alkaline phosphatase (ALP; Mabtech),
and 5-bromo-4-chloro-3-indolyl phosphate/nitro blue
tetrazolium, BCIP/NBT (Sigma-Aldrich). The mem-
branes of ELISPOT plates were treated with 15 μl 70%
ethanol followed by 8 washes with water and then
coated with detection Ab diluted 1:250 in PBS overnight
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at 4°C. The plates were washed with PBS and the
membrane blocked with complete cell culture medium
(RPMI1640 with 10% heat inactivated FCS, 2 mM
L-glutamine, 50 μM 2-mercaptoethanol, 100 U/ml peni-
cillin, 100 μg/ml streptomycin sulfate) for a minimum of
2 h at room temperature. Splenocytes, plated at 1 × 105
per well in 200 μl, were stimulated with Mtb antigens in-
cluding Mtb Erdman culture filtrate protein (CFP), BCG
CFP, and BCG heat-killed whole cell (WC). All Mtb anti-
gens were used at 2 μg/ml. A combination of Phorbol
12-myristate 13-acetate (PMA, 20 ng/ml) and ionomycin
(1 μM), both purchased from Sigma, was used for non-
specific T cell stimulation. After 44 h incubation (37°C,
5% CO2) cells were washed off the membrane with PBS
and biotinylated detection Ab (1:200 in PBS-T20) was
added and incubated for 2 h at room temperature. The
wells were washed with PBS-T80 and then PBS before
incubation with streptavidin-ALP for 1 h at room tem-
perature followed by PBS wash and addition of BCIP/
NBT substrate. IFN-γ spots were developed for 7 to
12 min before a final wash with water. The membrane
was dried overnight at room temperature. Analysis was
performed with an automated ELISPOT reader (Immu-
noSpot, Cellular Technology Limited, Shaker Heights,
OH), using CTL ImmunoSpot Academic Software ver-
sion 4.0. Results were calculated as spots per 105 spleno-
cytes, and mean numbers of spots from duplicate wells
of each stimulation are reported.
ELISA
Splenocytes were plated in 48-well plates at 2 × 106 cells
in 1 ml of complete media. Cells were stimulated with
Mtb antigens and PMA/ionomycin as described above
for 4 days and the supernatants were collected and
stored at −70°C until use. Secreted IFN-γ levels were
assayed by ELISA according to the manufacturer’s proto-
col (R&D Systems, Minneapolis, MN).
CFU assay
Lungs were harvested and then homogenized in PBS-
T80 using a Bullet Blender homogenizer (Next Advance,
Inc., Averill Park, NY). The homogenates were serially
diluted, plated in duplicate on Middlebrook 7H11 agar
(DIFCO), and cultured at 37°C for 3 weeks. Colonies
were counted using a dissecting microscope at day 13
and 21 after plating.
Immunohistochemistry
Lungs were inflated and fixed with 10% buffered forma-
lin for 24 h and then processed for staining. Paraffin em-
bedded tissues were sectioned and mounted on slides.
Mounted slides were stained with hematoxylin & eosin
(H&E) for histopathology, and Ziehl–Neelsen staining for
Mtb detection. Immunostaining of slides was performed
with anti-human CD4 (Vector Laboratories, Burlingame,
CA, 1:100), anti-human CD8 (Dako, Carpinteria, CA,
1:80), anti-human CD68 (Dako, 1:500), anti-mouse F4/80
(AbD Serotec, Raleigh, NC, 1:50) and anti-PPD (Abcam,
Cambridge, MA, 1:100). Enzymatic antigen retrieval was
performed prior to immunostaining and Ab was detected
with Dako Envision + Dual link System-HRP (Dako).
Fluorescent detection of primary Abs was performed using
Alexa Fluor 555 goat anti rabbit IgG (Life technologies,
Grand Island, NY) at a 1:500 dilution for anti-PPD Ab,
and Alexa flour 488 or 555 Donkey anti-mouse IgG
(Life technologies) at 1:500 for anti-human CD4, CD8,
and CD68, and anti-mouse F4/80 Abs. Lung sections
were stained with ProLong Gold antifade reagent with
DAPI (4′,6-Diamidino-2-Phenylindole, dihydrochloride)
(Life technologies) as a counter stain. All staining was
performed by the Diabetes and Endocrinology Research
Center histopathology core facility at University of Mas-
sachusetts Medical School. Stained lung sections were
analyzed with a Nikon Eclipse E400 microscope (Nikon In-
struments, Melville, NY) using Spot Advanced v.4.6 soft-
ware (Diagnostic Instruments Inc., Sterling Heights, MN).
Statistical analysis
Statistical analysis was performed using Graph Pad Prism
v.5.02 (Graphpad Software Inc., La Jolla, CA) software.
Unless otherwise stated, data from independent experi-
ments are shown as mean ± SEM. Comparisons between
groups were evaluated with Student t-test or One-way
ANOVA test followed by Dunnett's Multiple Comparison
Test. Bacterial load data were transformed using natural
logarithms to better approximate normally distributed
errors. A p value of 0.05 or lower was regarded as statis-
tically significant.
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